{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:02:14Z","timestamp":1791820934249,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-026-04017-4","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T18:46:04Z","timestamp":1771613164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual-mechanism preventive therapy in chronic migraine: an exploratory meta-analysis of onabotulinumtoxinA and anti-CGRP monoclonal antibody combination"],"prefix":"10.1186","volume":"31","author":[{"given":"Abbas","family":"Sarvari Soltani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Soroush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Noroozi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdiyeh","family":"Nozad Varjovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Mirmazloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Rigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyoosha","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Javadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Fatahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Asadi Anar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Elahabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Ahmadlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"4017_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.705276","volume":"2","author":"TJ Mungoven","year":"2021","unstructured":"Mungoven TJ, Henderson LA, Meylakh N. Chronic migraine pathophysiology and treatment: a review of current perspectives. Front Pain Res (Lausanne). 2021;2:705276.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"1","key":"4017_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1066-0","volume":"20","author":"AP Andreou","year":"2019","unstructured":"Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019;20(1):117.","journal-title":"J Headache Pain"},{"issue":"1","key":"4017_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s10194-024-01889-x","volume":"25","author":"A Raggi","year":"2024","unstructured":"Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G, et al. Hallmarks of primary headache: part 1\u2014migraine. J Headache Pain. 2024;25(1):189.","journal-title":"J Headache Pain"},{"issue":"1","key":"4017_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D. The Global Burden of Migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther. 2025;14(1):297\u2013315.","journal-title":"Pain Ther"},{"issue":"1","key":"4017_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-025-04122-7","volume":"25","author":"DC L\u00f3pez-Medina","year":"2025","unstructured":"L\u00f3pez-Medina DC, Arboleda-Ram\u00edrez A, R\u00edos-D\u00edaz S, Zambrano-Cruz R, Arboleda-Jaramillo A, Betancur-Henao C, et al. Cognition, mental health, and quality of life in patients with chronic and episodic migraine during the interictal period. BMC Neurol. 2025;25(1):108.","journal-title":"BMC Neurol"},{"issue":"3","key":"4017_CR6","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/neurolint15030067","volume":"15","author":"H Ple\u0219","year":"2023","unstructured":"Ple\u0219 H, Florian IA, Timis TL, Covache-Busuioc RA, Glavan LA, Dumitrascu DI, et al. Migraine: advances in the pathogenesis and treatment. Neurol Int. 2023;15(3):1052\u2013105.","journal-title":"Neurol Int"},{"issue":"2","key":"4017_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608","volume":"45","author":"S Sacco","year":"2025","unstructured":"Sacco S, Ashina M, Diener H-C, Haghdoost F, Lee MJ, Monteith TS, et al. Setting higher standards for migraine prevention: a position statement of the International Headache Society. Cephalalgia. 2025;45(2):03331024251320608.","journal-title":"Cephalalgia"},{"issue":"1","key":"4017_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01712-7","volume":"25","author":"C Tana","year":"2024","unstructured":"Tana C, Raffaelli B, Souza MNP, de la Torre ER, Massi DG, Kisani N, et al. Health equity, care access and quality in headache\u2014part 1. J Headache Pain. 2024;25(1):12.","journal-title":"J Headache Pain"},{"issue":"1","key":"4017_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01699-7","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Rubio-Beltr\u00e1n E, Cho S-J, De Icco R, Labastida-Ramirez A, Onan D, et al. Health equity, care access and quality in headache\u2014part 2. J Headache Pain. 2023;24(1):167.","journal-title":"J Headache Pain"},{"issue":"1","key":"4017_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/head.14244","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. 2022;62(1):106\u20138.","journal-title":"Headache"},{"issue":"6","key":"4017_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40263-024-01086-z","volume":"38","author":"A Salim","year":"2024","unstructured":"Salim A, Hennessy E, Sonneborn C, Hogue O, Biswas S, Mays M, et al. Synergism of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in the treatment of chronic migraine: a real-world retrospective chart review. CNS Drugs. 2024;38(6):481\u201391.","journal-title":"CNS Drugs"},{"issue":"6","key":"4017_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/head.13843","volume":"60","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale? Headache. 2020;60(6):1056\u201365.","journal-title":"Headache"},{"key":"4017_CR13","doi-asserted-by":"publisher","first-page":"1292994","DOI":"10.3389\/fpain.2023.1292994","volume":"4","author":"L Pellesi","year":"2023","unstructured":"Pellesi L. Combining onabotulinumtoxin A with a CGRP antagonist for chronic migraine prophylaxis: Where do we stand? Front Pain Res. 2023;4:1292994.","journal-title":"Front Pain Res"},{"key":"4017_CR14","doi-asserted-by":"publisher","first-page":"788159","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2022","unstructured":"Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2022;12:788159.","journal-title":"Front Neurol"},{"issue":"12","key":"4017_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14120847","volume":"14","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022;14(12):847.","journal-title":"Toxins"},{"issue":"1","key":"4017_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02106-z","volume":"26","author":"D Scuteri","year":"2025","unstructured":"Scuteri D, Pagliaro M, Iannacchero R, Trimboli M, Lawrence GW, Bagetta G, et al. Comparing eptinezumab with onabotulinumtoxinA in the treatment of chronic migraine: a real-world evidence study. J Headache Pain. 2025;26(1):159.","journal-title":"J Headache Pain"},{"key":"4017_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4017_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14120847","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. OnabotulinumtoxinA add-on to monoclonal anti-CGRP antibodies in treatment-refractory chronic migraine. Toxins. 2022. https:\/\/doi.org\/10.3390\/toxins14120847.","journal-title":"Toxins"},{"key":"4017_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01636-8","author":"L Charleston","year":"2023","unstructured":"Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, et al. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study. J Headache Pain. 2023. https:\/\/doi.org\/10.1186\/s10194-023-01636-8.","journal-title":"J Headache Pain"},{"issue":"2","key":"4017_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/03331024211034508","volume":"42","author":"D Martinelli","year":"2022","unstructured":"Martinelli D, Arceri S, De Icco R, Allena M, Guaschino E, Ghiotto N, et al. BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. Cephalalgia. 2022;42(2):170\u20135.","journal-title":"Cephalalgia"},{"key":"4017_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251332519","author":"R Mas-de-les-Valls","year":"2025","unstructured":"Mas-de-les-Valls R, G\u00f3mez-Dab\u00f3 L, Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, et al. Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: the unmet need of perimenstrual headache days. Cephalalgia. 2025. https:\/\/doi.org\/10.1177\/03331024251332519.","journal-title":"Cephalalgia"},{"issue":"2","key":"4017_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/cc.2024.15767","volume":"34","author":"D Mascarella","year":"2024","unstructured":"Mascarella D, Carandente B, Favoni V, Bruno EM, Cortelli P, Pierangeli G, et al. Back to the future: a case series on revisiting onabotulinumtoxinA for chronic migraine management after anti-CGRP therapies failure. Confinia Cephalalgica. 2024;34(2):1\u20136.","journal-title":"Confinia Cephalalgica"},{"issue":"1","key":"4017_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment\u2014real world outcomes. J Headache Pain. 2021;22(1):5.","journal-title":"J Headache Pain"},{"issue":"9","key":"4017_CR24","first-page":"1157","volume":"27","author":"SJ Tepper","year":"2021","unstructured":"Tepper SJ, Fang J, Abdrabboh A, Glassberg MB, Zhou L, Shen Y, et al. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the united states. J Manag Care Spec Pharm. 2021;27(9):1157\u201370.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"4017_CR25","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1007\/s10072-021-05547-x","volume":"42","author":"T Toni","year":"2021","unstructured":"Toni T, Tamanaha R, Newman B, Liang Y, Lee J, Carrazana E, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci. 2021;42(12):5373\u20136.","journal-title":"Neurol Sci"},{"issue":"6","key":"4017_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0333102420912726","volume":"40","author":"SJ Tepper","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein SD, et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020;40(6):543\u201353.","journal-title":"Cephalalgia"},{"issue":"1","key":"4017_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","volume":"22","author":"J Talbot","year":"2021","unstructured":"Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment\u2014real world outcomes. J Headache Pain. 2021;22(1):5.","journal-title":"J Headache Pain"},{"issue":"2","key":"4017_CR28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, et al. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci. 2022;43(2):1273\u201380.","journal-title":"Neurol Sci"},{"issue":"4","key":"4017_CR29","doi-asserted-by":"publisher","first-page":"333102425133251","DOI":"10.1177\/03331024251332519","volume":"45","author":"R Mas-de-Les-Valls","year":"2025","unstructured":"Mas-de-Les-Valls R, G\u00f3mez-Dab\u00f3 L, Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, et al. Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: the unmet need of perimenstrual headache days. Cephalalgia. 2025;45(4):3331024251332519.","journal-title":"Cephalalgia"},{"issue":"1","key":"4017_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-023-01636-8","volume":"24","author":"L Charleston","year":"2023","unstructured":"Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, et al. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study. J Headache Pain. 2023;24(1):101.","journal-title":"J Headache Pain"},{"key":"4017_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33425\/2639-846X.1037","volume":"4","author":"G Boudreau","year":"2020","unstructured":"Boudreau G. Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 2020;4:1\u20134.","journal-title":"Anesth Pain Res"},{"issue":"2","key":"4017_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/cc.2024.15767","volume":"34","author":"D Mascarella","year":"2024","unstructured":"Mascarella D, Carandente B, Favoni V, Bruno EM, Cortelli P, Pierangeli G, et al. Back to the future: a case series on revisiting onabotulinumtoxinA for chronic migraine management after anti-CGRP therapies failure. Confinia Cephalalgica. 2024;34(2):1\u20136.","journal-title":"Confinia Cephalalgica"},{"issue":"7","key":"4017_CR33","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793\u2013803.","journal-title":"Cephalalgia"},{"issue":"7","key":"4017_CR34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804\u201314.","journal-title":"Cephalalgia"},{"issue":"6","key":"4017_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921\u201336.","journal-title":"Headache"},{"issue":"22","key":"4017_CR36","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"4017_CR37","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123\u201332.","journal-title":"N Engl J Med"},{"issue":"10161","key":"4017_CR38","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137.","journal-title":"Lancet"},{"issue":"10","key":"4017_CR39","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1526-4610.2011.02022.x","volume":"51","author":"PL Durham","year":"2011","unstructured":"Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011;51(10):1573\u20137.","journal-title":"Headache"},{"issue":"24","key":"4017_CR40","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology"},{"issue":"1","key":"4017_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01925-w","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Garcia-Azorin D, Rubio-Beltr\u00e1n E, Ha W-S, Messina R, Ornello R, et al. Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain. 2024;25(1):214.","journal-title":"J Headache Pain"},{"issue":"2","key":"4017_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40263-022-00983-5","volume":"37","author":"LF Iannone","year":"2023","unstructured":"Iannone LF, Fattori D, Marangoni M, Benemei S, Chiarugi A, Geppetti P, et al. Switching onabotulinumtoxinA to monoclonal anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs. 2023;37(2):189\u2013202.","journal-title":"CNS Drugs"},{"issue":"2","key":"4017_CR43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326.","journal-title":"Pain Ther"},{"issue":"4","key":"4017_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1017\/cjn.2021.153","volume":"49","author":"G Boudreau","year":"2022","unstructured":"Boudreau G, Finkelstein I, Graboski C, Ong M, Christie S, Sommer K, et al. OnabotulinumtoxinA improves quality of life in chronic migraine: the PREDICT study. Can J Neurol Sci\/J Can Sci Neurol. 2022;49(4):540\u201352.","journal-title":"Can J Neurol Sci\/J Can Sci Neurol"},{"issue":"4","key":"4017_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64(4):333\u201341.","journal-title":"Headache"},{"issue":"4","key":"4017_CR46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496\u2013505.","journal-title":"Headache"},{"issue":"8","key":"4017_CR47","first-page":"818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States. J Manag Care Spec Pharm. 2022;28(8):818\u201329.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"4017_CR48","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1007\/s42399-021-00868-6","volume":"3","author":"AG Voloshin","year":"2021","unstructured":"Voloshin AG, Moiseeva IV. Combined interventional treatment of refractory chronic migraine. SN Compr Clin Med. 2021;3(6):1320\u20136.","journal-title":"SN Compr Clin Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04017-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04017-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:02:09Z","timestamp":1774620129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04017-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4017"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04017-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}